299 related articles for article (PubMed ID: 33232972)
21. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
[TBL] [Abstract][Full Text] [Related]
22.
Masle-Farquhar E; Jeelall Y; White J; Bier J; Deenick EK; Brink R; Horikawa K; Goodnow CC
Front Immunol; 2023; 14():1095257. PubMed ID: 36960072
[TBL] [Abstract][Full Text] [Related]
23. The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.
McCully RR; Pomerantz JL
Mol Cell Biol; 2008 Sep; 28(18):5668-86. PubMed ID: 18625728
[TBL] [Abstract][Full Text] [Related]
24. Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly.
Stinson JR; Dorjbal B; McDaniel DP; David L; Wu H; Snow AL
Cell Immunol; 2020 Jul; 353():104129. PubMed ID: 32473470
[TBL] [Abstract][Full Text] [Related]
25. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
27. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
28. Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.
Liu F; Karube K; Kato H; Arita K; Yoshida N; Yamamoto K; Tsuzuki S; Kim W; Ko YH; Seto M
Int J Clin Exp Pathol; 2012; 5(5):436-41. PubMed ID: 22808296
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
30. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
[TBL] [Abstract][Full Text] [Related]
31. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
Thompson RC; Herscovitch M; Zhao I; Ford TJ; Gilmore TD
J Biol Chem; 2011 Jan; 286(3):1675-82. PubMed ID: 20947507
[TBL] [Abstract][Full Text] [Related]
32. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
33. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
34. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
35. Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.
Wang Z; Hutcherson SM; Yang C; Jattani RP; Tritapoe JM; Yang YK; Pomerantz JL
J Biol Chem; 2019 Oct; 294(40):14648-14660. PubMed ID: 31391255
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
[TBL] [Abstract][Full Text] [Related]
37. VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.
Nichele I; Zamò A; Bertolaso A; Bifari F; Tinelli M; Franchini M; Stradoni R; Aprili F; Pizzolo G; Krampera M
PLoS One; 2012; 7(12):e52811. PubMed ID: 23285191
[TBL] [Abstract][Full Text] [Related]
38. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
39. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O; Beylot-Barry M; Pham-Ledard A; Bohers E; Viailly PJ; Bandres T; Faur N; Frison E; Vergier B; Jardin F; Merlio JP; Gros A
J Invest Dermatol; 2019 Nov; 139(11):2334-2342.e8. PubMed ID: 31150604
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
